Literature DB >> 22645878

Postdeployment behavioral health screening: face-to-face versus virtual behavioral health interviews.

Maurice L Sipos1, Heather M Foran, Maria L Crane, Michael D Wood, Kathleen M Wright.   

Abstract

Virtual behavioral health (VBH) services are used frequently to address the high demand for behavioral health (BH) services in the military. Few studies have investigated the relationship between the use of VBH services and BH outcomes or preferences for the use of VBH technologies. In this article, we evaluated BH interviews conducted via video teleconferencing (VTC) or face-to-face in terms of BH symptoms, satisfaction rates, stigma, barriers to care, and preferences for future use of BH care. Soldiers (n = 307) from the headquarters element of an operational unit were surveyed 4 months following a 12-month deployment to Iraq. There were no significant differences in satisfaction rates based on interview modality, but significantly more soldiers preferred face-to-face interviews over VTC interviews in the future. Soldiers who preferred face-to-face interviews also reported higher levels of anxiety and depression symptoms than those who preferred VTC interviews. No significant age differences were found in terms of interview modality satisfaction or preference. Soldiers with greater deployment experience were more likely to report that they would not like using VTC if seeking BH care in the future than soldiers with less deployment experience. These findings highlight the importance of promoting choice in type of BH interview modality.

Entities:  

Mesh:

Year:  2012        PMID: 22645878     DOI: 10.7205/milmed-d-11-00399

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  Stigmatisation, perceived barriers to care, help seeking and the mental health of British Military personnel.

Authors:  Norman Jones; Mary Keeling; Gursimran Thandi; Neil Greenberg
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-09-15       Impact factor: 4.328

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.